In a retrospective cohort study of more than 17,000 patients with hormone receptor (HR)-positive, HER2-negative breast cancer, changes in the treatment paradigm have more young patients receiving ovarian suppression as part of initial therapy, and patients regardless of age receiving treatment with the CDK4/6 inhibitor palbociclib, whereas a decrease has been seen in use of tamoxifen for younger patients and overall.
In the MONALEESA-2 study, the CDK4/6 inhibitor ribociclib, in combination with letrozole, led to significant prolongation of progression-free survival while maintaining quality of life in postmenopausal women with advanced breast cancer.
Page 4 of 4
Results 31 - 32 of 32